Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma

Table 3 The relationship between response intensity of HPV E1-specific T cell response in peripheral blood and the clinical features in patients with cervical squamous cell carcinoma

Factor		N	Mean magnitude (SFC/10⁶)	Z	P-value
Age (year)	≤54	32	20.06	−0.598	0.550
Age (year)	> 54	34	28.05	−0.598	0.550
Family history of cancer	No	59	24.74	−0.570	0.568
Family history of cancer	Yes	7	23.4	−0.570	0.568
History of miscarriage	No	30	24.88	−0.570	0.569
History of miscarriage	Yes	36	24.32	−0.570	0.569
Tumor size (cm)	≤5	43	23.4	−0.662	0.508
Tumor size (cm)	> 5	23	26.64	−0.662	0.508
Tumor type	Cauliflower	25	24.77	−0.115	0.909
	Nodular	29	24.65
	Hollow	7	24.6
	Others	5	23.5
Histologic grade	Well	2	0	−1.826	0.068
	Moderate	45	21.31
	Poor	13	39.28
	Papillary	6	21.67
FIGO stage	IIB	34	27.45	−2.077	0.038
FIGO stage	IIIA-IIIB	32	21.53	−2.077	0.038
SCC-Ag	Normal	12	23	−0.419	0.675
SCC-Ag	Anormal	54	25.03	−0.419	0.675
CEA	Normal	42	22.56	−1.239	0.215
CEA	Anormal	24	29.08	−1.239	0.215
TSGF	Normal	46	30.72	−1.958	0.050
TSGF	Anormal	20	13.57	−1.958	0.050
Pelvic lymph nodes	No	37	25.58	−2.017	0.044
Pelvic lymph nodes	Yes	29	22.93	−2.017	0.044

N number of patients, Mean magnitude of T cell response of the population, FIGO International Federation of Gynecology and Obstetrics, SCC-Ag Squamous cell carcinoma antigen, CEA carcinoembryonic antigen, TSGF Tumor specific growth factor

ISSN: 1750-9378